Lindbrook Capital’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Lindbrook Capital’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,278	Closed	-$5.21K	–	2885
2023 Q1	$5.21K	Buy	1,278 +231	+22%	+$1.07K	﹤0.01%	1837
2022 Q4	$5.26K	Buy	1,047 +866	+478%	+$5.43K	﹤0.01%	1800
2022 Q3	$2K	Sell	181 -42	-19%	-$636	﹤0.01%	2184
2022 Q2	$3K	Buy	223 +88	+65%	+$1.22K	﹤0.01%	1875
2022 Q1	$2K	Buy	135 +64	+90%	+$998	﹤0.01%	2124
2021 Q4	$1K	Hold	71	–	–	﹤0.01%	2033
2021 Q3	$1K	Hold	71	–	–	﹤0.01%	1818
2021 Q2	$1K	Hold	71	–	–	﹤0.01%	1867
2021 Q1	$2K	Hold	71	–	–	﹤0.01%	1635
2020 Q4	$2K	Hold	71	–	–	﹤0.01%	1537
2020 Q3	$1K	Hold	71	–	–	﹤0.01%	1692
2020 Q2	$1K	Hold	71	–	–	﹤0.01%	1662
2020 Q1	$1K	Sell	71 -1	-1%	-$16	﹤0.01%	1610
2019 Q4	$1K	Buy	+72	New	+$1.05K	﹤0.01%	1464

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lindbrook Capital's NGM Position: Q2 2023 in Review

Lindbrook Capital sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 1,278 shares — an estimated $5.21K sold.

Lindbrook Capital first reported a position in NGM in Q4 2019 and held it in 14 quarters. The position peaked at $5.26K in Q4 2022. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

Lindbrook Capital reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Lindbrook Capital sold 1,278 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $5.21K.
Lindbrook Capital first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
Lindbrook Capital's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $5.26K in Q4 2022.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.